Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Wong, Michael K

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. [electronic resource] - Current medical research and opinion Apr 2014 - 537-45 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1473-4877

10.1185/03007995.2013.871243 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Carcinoma, Renal Cell--drug therapy
Disease-Free Survival
Everolimus
Female
Humans
Kidney Neoplasms--drug therapy
Male
Middle Aged
Niacinamide--analogs & derivatives
Phenylurea Compounds--therapeutic use
Proportional Hazards Models
Protein Kinase Inhibitors--therapeutic use
Retrospective Studies
Sirolimus--analogs & derivatives
Sorafenib
Treatment Outcome